Martin AJ, et al. – Researchers evaluated whether this progression–free survival (PFS) gains had the potential to be offset by the quality of life (QoL) impacted from treatment side effects and to thereby determine the appropriateness of continuing development to phase III. Without an excessively negative effect on QoL, regorafenib improved deterioration–free survival (DFS). Progressing development to the phase III setting was warranted.